LexisPSL
Crucial Development on the Presumption of Confidentiality in the Access to Document Saga (PTC Therapeutics v EMA and MSD Animal Health Innovation, Intervet v EMA)
September 19, 2019
The saga of access to documents (ATD) cases in the European pharmaceutical legal landscape continues, this time with two promising opinions of Advocate-General Hogan. In summary AG Hogan found that the General Court had erred in law in its conclusions that (a) there was no general presumption of confidentiality and (b) access to the study reports submitted in a marketing authorisation application dossier at issue would not compromise the applicants’ commercial interests.
This article has been originally published on LexisPSL.
Contacts

Capabilities
Suggested News & Insights
GMP 2026: Regulatory Reliance, AI, and the Future of Pharmaceutical ManufacturingWednesday, December 2, 2026A New World Order – Market Access, MFN, and GeopoliticsTuesday, November 10, 2026Sidley & Trinity Capital Life Sciences ReceptionThursday, October 22, 2026California Adopts Regulations Expanding Healthcare Transaction ReviewOctober 8, 20262025 to First-Half 2026 Marks a Breakout Time for CVRsOctober 7, 2026Sidley Represents GE HealthCare in Its US$945 Million Acquisition of SOFIE BiosciencesOctober 7, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory